Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
METADATA ONLY
Loading...
Author / Producer
Date
2020-03
Publication Type
Journal Article
ETH Bibliography
no
Citations
Altmetric
METADATA ONLY
Data
Rights / License
Abstract
Background: Approved drugs must be included on the so-called “special list” (SL) by the Federal Office for Public Health (FOPH) to be reimbursed by the social health insurance in Switzerland. The FOPH decides whether a drug may be included on SL and if so, negotiates the maximum price with the manufacturer. Time period between approval and inclusion on SL is important to evaluate accessibility of patients to drugs.
Permanent link
Publication status
published
Editor
Book title
Journal / series
Volume
124 (3)
Pages / Article No.
261 - 267
Publisher
Elsevier
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Cancer drugs; approval; reimbursement; Price negotiation; Health policy; Public health
Organisational unit
09853 - Vokinger, Kerstin Noëlle / Vokinger, Kerstin Noëlle